ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC) Meeting Abstract
| Authors: | Tripathy, D.; Sara, T.; Seidman, A. D.; Anders, C. K.; Ibrahim, N.; Rugo, H. S.; Twelves, C. J.; Diéras, V.; Müller, V.; Hannah, A.; Tagliaferri, M.; Cortés, J. |
| Abstract Title: | ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC) |
| Meeting Title: | 40th Annual San Antonio Breast Cancer Symposium (SABCS 2017) |
| Journal Title: | Cancer Research |
| Volume: | 78 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2017 Dec 5-9 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2018-02-01 |
| Language: | English |
| ACCESSION: | WOS:000425489400099 |
| PROVIDER: | wos |
| DOI: | 10.1158/1538-7445.SABCS17-OT2-07-10 |
| Notes: | Meeting Abstract: OT2-07-10 -- Source: Wos |
